Resumen

Objectives: Change our mindset on skin aging interventions to pro-longevity approaches, supporting skin's natural ability to repair by delaying senescence and the need for regenerative therapies. Introduction: Fibroblast exhaustion plays a major role in developing signs of skin aging. Currently most anti-aging interventions stimulate exhausted fibroblasts, leading to inefficient and transient benefit. Stimulating cellular repair resets fibroblast to a healthy and more youthful state, which then responds better to all anti-aging interventions designed to stimulate fibroblast function. Extending a healthy lifespan, also defined as LONGEVITY, reduces the need for replacement thereby preserving progenitor cell population for true skin longevity. Materials / method: RLX-201, a selective inhibitor of the TORC1 multiprotein complex of mTOR, accelerates fibroblast repair in donor fibroblasts cultures, reconstituted skin models and excised human skin. Inhibition of TORC1 is documented to increase cellular longevity by a pan-hallmarks approach, with a potential to provide durable skin health benefits when used alone or in combination with other fibroblast-stimulating anti-aging interventions. A 12-week double-blind, vehicle-controlled clinical study verified the benefits of the approach with rapid benefits in elasticity and skin quality parameters. Results: RLX-201 improves the morphology and biomarker profile of human dermal from 23 and 56 years old donors to younger phenotype. Re-Q Pro-Longevity Face Serum containing RLX-201 demonstrates a 60% reduction in TORC1 activity in excised human skin after topical application. Clinical study shows a rapid improvement in all elasticity-related outcomes as early as 2 weeks with statistical significance over vehicle starting at 4 weeks. Skin quality parameters show consistent and statically significant improvements over vehicle throughout the 12-week study. The product was very well tolerated. Conclusion: TORC1 inhibition by RLX-201 shifts the morphology and biomarker profile of human dermal fibroblasts to a younger phenotype, demonstrating increased longevity. Product containing RLX-201 provides rapid and significant clinical benefits over a matched vehicle in skin elasticity and other skin quality parameters. The in-vitro and clinical results strongly suggest that CELLULAR RESET is possible with the right intervention and a promise of accelerated clinical benefits from existing anti-aging interventions.